Method
Level · gp.fundamentals.debt_to_revenue
Raw value 93.56% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTMADRIGAL PHARMACEUTICALS, INC.'s latest supported as-filed period reports revenue of $364.3M, 71.2% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 93.56% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 1.17% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 6.40% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 71.17% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 27.29% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -15.46% · CORE
Level · gp.fundamentals.sbc_revenue_ratio
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +57.2% from the comparable as-filed period.
Debt changed +187.9% from the comparable as-filed period. The change ranks at the 57th percentile of 7 prior comparable changes.
Inventory changed +56.5% from the comparable as-filed period.
Net income changed -37.0% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
MDGL · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001628280-26-058256SEC ↗4Aug 18, 2026Period Aug 15, 20260001628280-26-057751SEC ↗8-KAug 12, 2026Period Aug 11, 20260001628280-26-055962SEC ↗10-QJul 30, 2026Period Jun 30, 20260001628280-26-050845SEC ↗8-KJul 30, 2026Period Jul 30, 20260001628280-26-050775SEC ↗4Jul 20, 2026Period Jul 17, 20260001628280-26-048919SEC ↗4Jun 18, 2026Period Jun 17, 20260001628280-26-044346SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 17, 2026Filed Aug 20, 2026 | Kelley Shannon TGeneral Counsel | Open Market SaleDirect | 664 | $515 | $341,940 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 9.71% · OPTIONAL
Operating income changed -19.3% from the comparable as-filed period.
Operating margin changed +672 basis points from the comparable as-filed period.
Revenue changed +71.2% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001628280-26-044340